Alzheimer's Drug Discovery Foundation

We are deeply saddened to share the passing of ADDF Co-Founder Leonard A. Lauder. Alongside his brother, Leonard founded the ADDF in 1998, transforming the Alzheimer's research landscape through their vision, catalytic funding, venture philanthropy. bit.ly/4kCet2h.

Tune in to the latest episode of @Biotech2050Pod as @TheADDFCEO and @a_hfillit share how the ADDF is pioneering early detection, bold funding strategies, and the future of treatment.

Ahead of #AAIC2025, @a_fillit shares how patients now have access to new treatments in the U.S, yet the regulatory approvals in Europe face delays. Alzheimer's has entered a new era and now is the time to invest in scalable, cost-effective treatments. bit.ly/3GIBfXH

ADDF board member, @PhylFerrell, shares with @Forbes her journey navigating her father’s Alzheimer’s diagnosis and how Alzheimer’s care and research have entered a new era driven by breakthroughs in treatments and diagnostics with recent FDA approvals. bit.ly/450GMAG

Congratulations to our friends and partners at Gates Ventures on their flagship publication from @_neuroproteome in @Nature, marking the global release of the GNPC harmonized dataset (v1), bringing us closer to how we detect, track and treat diseases like #Alzheimer’s.

What’s next for biotech in 2025? In @PMLiVEcom, Karen Harris dives into how market pressures are redefining breakthroughs in Alzheimer’s treatment with evolving funding shifts, policy changes and key investments. bit.ly/3GPKVj5

Your brain changes as you age, but so can your habits. Yuko Hara shares with @HuffPost how our brains evolve with age, gaining wisdom and perspective, and why lifestyle interventions like diet play a crucial role in Alzheimer’s prevention. bit.ly/4law4yw

At #BIO2025, Karen Harris highlighted #biotech funding challenges, which started long before the NIH cuts, underscoring the urgent need for alternative capital pathways to sustain the biotech ecosystem. @cenmag bit.ly/4l5T7uk

The Alzheimer’s drug pipeline is more robust than ever, moving beyond amyloid, with 138 novel drugs in 182 clinical trials targeting new biology of aging pathways, including inflammation, tau proteins, vascular health and more. @Medscape @DrJeffCummings wb.md/4lJh62p

On the latest @INVIVOnow, Karen Harris, joins @davidwild77 to discuss ADDF’s investment strategy, biotech & investor sentiment from #BIO2025, and what’s next in #Alzheimer’s innovation. Listen now! bit.ly/4eHkNU6

Karen Harris chats with @PharmaVoice about the evolving biotech landscape, the recent challenges and latest developments. “There’s so much opportunity right now, I see a lot of promise ahead for therapies based on the biology of aging.” #BIO2025 bit.ly/4ny5rVS

Today, the FDA approved an updated label for Kisunla for early-stage Alzheimer’s, with a new dosing schedule to lower ARIA risk, marking a critical step in clinical care and moving us closer to combination therapy and precision medicine. @EliLillyandCo bit.ly/407MBej

Exciting news from our funded investigators @CircGenomics! Our investment is advancing circRNA, a novel blood-based biomarker for diagnosing and predicting Alzheimer's progression, supported by Diagnostics Accelerators (DxA).

Dr. Fillit, discusses how the new Lumipulse blood test—developed by Fujirebio and funded by the Diagnostics Accelerators (DxA)— is revolutionizing Alzheimer’s diagnostics. For the first time, tools are affordable, accessible, and scalable. @NeurologyToday bit.ly/4knzLj5

Alzheimer’s is at a pivotal moment, and so is the science behind it. In a new interview with @WuXi_AppTec, Dr. Howard Fillit shares how we're entering a new era in Alzheimer's research, driven by early detection, innovative science and bold funding models. bit.ly/45Bjun6

From combination therapies to cutting-edge blood tests, Karen Harris highlights the ADDF’s pivotal role in the Alzheimer’s ecosystem, sharing key insights into where the field is headed and how the ADDF is leading the science to bring us what comes next. pharmexec.com/view/fight-alz…

In @statnews, @BillGates highlights progress in early detection & Alzheimer’s treatment. The FDA approval of the first blood test, supported by ADDF’s DxA, represents a transformative advance for clinical trials, therapies, and patient hope. bit.ly/44r4yGY

A new study published in @journal_ad links Ozempic to a lower Alzheimer’s risk in type 2 diabetes. Building on Dr. Edison’s ADDF-funded liraglutide trial, these findings highlight the growing connection between metabolic and brain health. @Newsweek bit.ly/44yy5Pb

The FDA approved an updated label for Amyvid, a brain imaging diagnostic that detects amyloid. Developed by Goodes Prize Winner Dan Skovronsky & supported by ADDF, this will help physicians detect amyloid buildup earlier and guide treatment. @EliLillyandCo bit.ly/44fYSOU

@ADDFCEO & Dr. Fillit of ADDF joined @aloktayi on @Biotech2050Pod for a powerful convo on the future of Alzheimer’s innovation: – ADDF’s venture philanthropy model – Urgency of risk-taking in drug development – Innovation amid federal funding pressure bit.ly/4086SAc

⸻ I waited to post, honoring Leonard Lauder’s passing. Then Bill Gates shared this note on Alzheimer’s and the ADDF: 🔗 people.com/5-years-after-… Leonard once told Bill: “I’m too old to buy green bananas. Let’s start the Diagnostics Accelerator together.” The rest is history.…